SCHEMBL31286690

SCHEMBL31286690

COC(=O)c1cc(-c2cnc(Cl)nc2)no1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
RAB9A P51151 5/20 0.40
NPC1 O15118 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NOTUM Q6P988 1/20 0.39
THRB P10828 3/20 0.38
LMNA P02545 2/20 0.38
TP53 P04637 1/20 0.38
KMT2A Q03164 2/20 0.37
CYP3A4 P08684 1/20 0.37
MEN1 O00255 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HTT P42858 1/20 0.37
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544560 0.77 MAPT (0.55) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL5293345 0.77 SMN1; SMN2 (0.63) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL31583966 0.77 MAPT (0.40) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL24461541 0.76 POLB (0.43) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL8880347 0.76 MAPT (0.52) MAPTSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL15919469 0.76 MAPT (0.60) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL13363878 0.76 CYP46A1 (0.49) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL13363888 0.75 CYP19A1 (0.51) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL30516592 0.75 CYP19A1 (0.51) MAPTSMN1; SMN2RAB9ANPC1CYP1A2
SCHEMBL17652591 0.75 MAPT (0.60) MAPTSMN1; SMN2RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747248-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION Institute of Cancer Research: Royal Cancer Hospital (The) (GB) 2026-05-27 EP disclosed
WO-2025022093-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2025-01-30 WO disclosed